Adrian Rawcliffe
2015
In 2015, Adrian Rawcliffe earned a total compensation of $2.9M as Chief Financial Officer at Adaptimmune Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $151,403 |
|---|---|
| Option Awards | $2,379,693 |
| Salary | $336,452 |
| Other | $42,387 |
| Total | $2,909,935 |
Rawcliffe received $2.4M in option awards, accounting for 82% of the total pay in 2015.
Rawcliffe also received $151.4K in non-equity incentive plan, $336.5K in salary and $42.4K in other compensation.
Rankings
In 2015, Adrian Rawcliffe's compensation ranked 3,285th out of 13,638 executives tracked by ExecPay. In other words, Rawcliffe earned more than 75.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,285 out of 13,638 | 76th |
Division Manufacturing | 1,192 out of 5,190 | 77th |
Major group Chemicals And Allied Products | 435 out of 1,854 | 77th |
Industry group Drugs | 345 out of 1,528 | 77th |
Industry Biological Products, Except Diagnostic Substances | 59 out of 254 | 77th |
Source: SEC filing on April 28, 2017.
Rawcliffe's colleagues
We found two more compensation records of executives who worked with Adrian Rawcliffe at Adaptimmune Therapeutics in 2015.